SG11201909895UA - Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles - Google Patents
Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 allelesInfo
- Publication number
- SG11201909895UA SG11201909895UA SG11201909895UA SG11201909895UA SG 11201909895U A SG11201909895U A SG 11201909895UA SG 11201909895U A SG11201909895U A SG 11201909895UA SG 11201909895U A SG11201909895U A SG 11201909895UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- alzheimer
- disease
- treatment
- receptor antagonist
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title abstract 3
- 108700028369 Alleles Proteins 0.000 title abstract 3
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 239000003751 serotonin 6 antagonist Substances 0.000 title abstract 3
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700313 | 2017-05-24 | ||
DKPA201700538 | 2017-09-29 | ||
PCT/EP2018/063402 WO2018215478A1 (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909895UA true SG11201909895UA (en) | 2019-11-28 |
Family
ID=62235961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909895U SG11201909895UA (en) | 2017-05-24 | 2018-05-22 | Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles |
Country Status (22)
Country | Link |
---|---|
US (1) | US11464759B2 (sl) |
EP (1) | EP3630098B1 (sl) |
JP (1) | JP7167065B2 (sl) |
KR (1) | KR102676011B1 (sl) |
CN (1) | CN111032038A (sl) |
AU (1) | AU2018272883B2 (sl) |
BR (1) | BR112019001145A2 (sl) |
CA (1) | CA3063968A1 (sl) |
CY (1) | CY1124282T1 (sl) |
DK (1) | DK3630098T3 (sl) |
ES (1) | ES2869128T3 (sl) |
HR (1) | HRP20210634T1 (sl) |
HU (1) | HUE053636T2 (sl) |
LT (1) | LT3630098T (sl) |
MX (1) | MX2019013912A (sl) |
PL (1) | PL3630098T3 (sl) |
PT (1) | PT3630098T (sl) |
RS (1) | RS61704B1 (sl) |
SG (1) | SG11201909895UA (sl) |
SI (1) | SI3630098T1 (sl) |
WO (1) | WO2018215478A1 (sl) |
ZA (1) | ZA201907525B (sl) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ3493A1 (fr) | 2001-03-29 | 2002-10-10 | Lilly Co Eli | N-(2-arylethyl)benzylamines comme antagonistes du recepteur 5-ht6 |
US20060160079A1 (en) * | 2002-08-07 | 2006-07-20 | Lane Roger M | Methods for the treatment of dementia based on apo e genotype |
KR101441725B1 (ko) | 2007-05-22 | 2014-09-18 | 오츠카 세이야쿠 가부시키가이샤 | 알츠하이머병 치료를 위한 카르보스티릴 유도체 및 도네페질을 포함하는 치료제 |
EP2254564A1 (en) | 2007-12-12 | 2010-12-01 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
RU2369600C1 (ru) | 2008-01-24 | 2009-10-10 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
ES2654930T3 (es) | 2009-04-13 | 2018-02-15 | Theravance Biopharma R&D Ip, Llc | Combinaciones de agonistas del receptor 5-HT4 y de inhibidores de la acetilcolinesterasa para el tratamiento de los trastornos cognitivos |
JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
US20160038484A1 (en) | 2013-04-03 | 2016-02-11 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
AU2016256923A1 (en) | 2015-05-07 | 2017-11-23 | Axovant Sciences Gmbh | Methods of treating a neurodegenerative disease |
HUE062626T2 (hu) * | 2016-04-26 | 2023-11-28 | H Lundbeck As | Acetilkolinészteráz inhibitor és idalopirirdin alkalmazása Parkinson-kóros páciensek elesésének csökkentésében |
US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
-
2018
- 2018-05-22 CN CN201880033314.8A patent/CN111032038A/zh active Pending
- 2018-05-22 PT PT187267919T patent/PT3630098T/pt unknown
- 2018-05-22 PL PL18726791T patent/PL3630098T3/pl unknown
- 2018-05-22 LT LTEP18726791.9T patent/LT3630098T/lt unknown
- 2018-05-22 ES ES18726791T patent/ES2869128T3/es active Active
- 2018-05-22 CA CA3063968A patent/CA3063968A1/en active Pending
- 2018-05-22 MX MX2019013912A patent/MX2019013912A/es unknown
- 2018-05-22 WO PCT/EP2018/063402 patent/WO2018215478A1/en active Application Filing
- 2018-05-22 KR KR1020197032218A patent/KR102676011B1/ko active IP Right Grant
- 2018-05-22 RS RS20210449A patent/RS61704B1/sr unknown
- 2018-05-22 AU AU2018272883A patent/AU2018272883B2/en active Active
- 2018-05-22 BR BR112019001145-5A patent/BR112019001145A2/pt active Search and Examination
- 2018-05-22 EP EP18726791.9A patent/EP3630098B1/en active Active
- 2018-05-22 SG SG11201909895U patent/SG11201909895UA/en unknown
- 2018-05-22 JP JP2019564834A patent/JP7167065B2/ja active Active
- 2018-05-22 HU HUE18726791A patent/HUE053636T2/hu unknown
- 2018-05-22 SI SI201830258T patent/SI3630098T1/sl unknown
- 2018-05-22 DK DK18726791.9T patent/DK3630098T3/da active
- 2018-05-23 US US15/987,449 patent/US11464759B2/en active Active
-
2019
- 2019-11-13 ZA ZA2019/07525A patent/ZA201907525B/en unknown
-
2021
- 2021-04-14 CY CY20211100328T patent/CY1124282T1/el unknown
- 2021-04-22 HR HRP20210634TT patent/HRP20210634T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
BR112019001145A2 (pt) | 2019-04-30 |
US20180353477A1 (en) | 2018-12-13 |
LT3630098T (lt) | 2021-05-25 |
AU2018272883A1 (en) | 2019-11-14 |
RS61704B1 (sr) | 2021-05-31 |
ZA201907525B (en) | 2022-02-23 |
HUE053636T2 (hu) | 2021-07-28 |
WO2018215478A1 (en) | 2018-11-29 |
EP3630098B1 (en) | 2021-03-24 |
KR20200007795A (ko) | 2020-01-22 |
PL3630098T3 (pl) | 2021-09-06 |
RU2019135609A3 (sl) | 2021-08-23 |
SI3630098T1 (sl) | 2021-07-30 |
CN111032038A (zh) | 2020-04-17 |
JP7167065B2 (ja) | 2022-11-08 |
RU2019135609A (ru) | 2021-06-24 |
CA3063968A1 (en) | 2018-11-29 |
JP2020520964A (ja) | 2020-07-16 |
MX2019013912A (es) | 2020-01-21 |
US11464759B2 (en) | 2022-10-11 |
KR102676011B1 (ko) | 2024-06-17 |
ES2869128T3 (es) | 2021-10-25 |
PT3630098T (pt) | 2021-04-21 |
EP3630098A1 (en) | 2020-04-08 |
CY1124282T1 (el) | 2022-07-22 |
HRP20210634T1 (hr) | 2021-05-28 |
AU2018272883B2 (en) | 2024-02-15 |
DK3630098T3 (da) | 2021-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201811559WA (en) | Cancer treatment combinations | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |